Corcept's ALS Drug Shows 87% Survival Benefit in Phase 2; Company Raises Full-Year Revenue Outlook
summarizeSummary
Corcept Therapeutics announced a mixed Q1 earnings report, swinging to a loss of $31.8 million, or $0.30 per share, and missing revenue estimates. However, the company provided a significant and positive update on its ALS treatment, dazucorilant. While the primary endpoint of the Phase 2 study was not met (a fact previously reported in December 2024), the company highlighted that patients receiving a higher dose experienced an 87% reduction in the risk of death over a two-year period, a highly material secondary endpoint. Corcept plans to initiate a pivotal Phase 3 study for dazucorilant later this year. Additionally, the company raised its full-year revenue outlook to a range of $950 million to $1.05 billion, surpassing analyst expectations. This comprehensive update, including the positive drug data and guidance raise, significantly reframes the narrative following recent negative news regarding Q1 revenue and the initial interpretation of the ALS trial.
At the time of this announcement, CORT was trading at $46.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5B. The 52-week trading range was $28.66 to $91.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.